Name | 1-({(5S,7S)-3-[5-(2-Hydroxy-2-propanyl)-2-pyrazinyl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]dec-7-yl}methyl)-1H-benzimidazole-6-carbonitrile |
---|---|
Synonyms |
1-({(5S,7S)-3-[5-(2-Hydroxy-2-propanyl)-2-pyrazinyl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]dec-7-yl}methyl)-1H-benzimidazole-6-carbonitrile
1H-Benzimidazole-6-carbonitrile, 1-[[(5S,7S)-3-[5-(1-hydroxy-1-methylethyl)-2-pyrazinyl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]dec-7-yl]methyl]- |
Description | GSK2798745 is a first-in-class, highly potent, selective, orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 is used in research for the treatment of pulmonary edema associated with congestive heart failure[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 1.8 nM (hTRPV4) and 1.6 nM (rTRPV4)[2] |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 682.1±65.0 °C at 760 mmHg |
Molecular Formula | C25H28N6O3 |
Molecular Weight | 460.528 |
Flash Point | 366.3±34.3 °C |
Exact Mass | 460.222290 |
LogP | 1.76 |
Vapour Pressure | 0.0±2.2 mmHg at 25°C |
Index of Refraction | 1.680 |
Storage condition | 2-8°C |